Magnefar
Name: Magnefar Pharmacological action: Magnefar is a complex preparation containing pyridoxine hydrochloride and magnesium. Magnefar helps restore magnesium levels in patients with magnesium deficiency, as well as normalize magnesium-dependent processes. Magnesium takes part in a number of metabolic processes in the body, including ATP-dependent enzymatic reactions, hormone metabolism, and stabilization of cell membranes. Magnesium is necessary for the normal functioning of the nervous, respiratory, cardiovascular, musculoskeletal and hematopoietic systems. Magnesium plays an important role in the functioning of the visual and auditory nerves. Magnesium maintains the normal state of the myocardium, including under conditions of hypoxia, has anticoagulant properties, and prevents hardening of blood vessels. In addition, magnesium has some calming activity and regulates neuromuscular excitability.
Pyridoxine hydrochloride is a B vitamin that regulates lipid, protein and carbohydrate metabolism. Pyridoxine hydrochloride takes part in the formation of hemoglobin. Magnesium and pyridoxine hydrochloride mutually enhance each other's effects, in addition, pyridoxine hydrochloride improves the intestinal absorption of magnesium and its penetration into cells. Pyridoxine is metabolized in the liver with the participation of magnesium to form the active substance - pyridoxal-5-phosphate.
Indications for use: Magnefar is intended for the treatment of patients with primary and secondary magnesium deficiency, including congenital magnesium deficiency, insufficient intake of magnesium from food, taking medications that can lead to magnesium deficiency, as well as a number of diseases in which the need for magnesium is increased or its excretion from the body is increased. Magnefar is also prescribed to patients suffering from excessive excitability, increased irritability, sleep disturbances, muscle spasms and fatigue (physical and intellectual), which are caused by magnesium deficiency.
Directions for use: Magnefar is intended for oral use. It is recommended to take the tablets with meals, without chewing and with plenty of drinking water. The duration of therapy and dose of Magnefar is determined by the doctor, taking into account the level of magnesium deficiency. Adults and adolescents are usually recommended to take 1-2 tablets of Magnefar three times a day. For children from 6 to 12 years old, as a rule, it is recommended to take 1 tablet of Magnefar twice or three times a day.
As a preventative measure, the drug Magnefar is prescribed in a daily dose of 1-2 tablets. Therapy should be continued until plasma magnesium concentrations normalize. If necessary, the course of therapy is repeated 1-2 times a year. If the patient has a concomitant calcium deficiency, then the level of magnesium in the body should be adjusted before starting calcium therapy.
Side effects: Magnefar, as a rule, does not cause the development of undesirable effects. However, the possibility of side effects cannot be ruled out (especially when taking high doses of magnesium). In particular, patients may develop the following side effects due to taking the drug Magnefar: From the cardiovascular system: arrhythmia, atrioventricular block, decreased blood pressure.
From the gastrointestinal tract: flatulence, pain and discomfort in the epigastric region, vomiting, nausea. Allergic reactions: urticaria, skin hyperemia. Side effects disappear after discontinuation of the drug Magnefar and do not require additional therapy.
Contraindications: Magnefar is not prescribed to patients with individual intolerance to the components of the drug. Magnefar is not used for the treatment of patients with hypervitaminosis B6 and elevated levels of magnesium in the blood plasma, as well as patients suffering from severe renal impairment, atrioventricular block, arterial hypotension (with systolic pressure less than 90 mmHg), myasthenia gravis and disorders intestinal absorption (including chronic diarrhea).
Magnefar should not be prescribed to patients with Parkinson's disease who are receiving levodopa without combination with peripheral levodopa decarboxylase inhibitors. Magnefar is not used in pediatric practice to treat children under 6 years of age. Magnefar is prescribed with caution to patients suffering from moderate renal impairment.
Pregnancy: Magnefar can be prescribed during pregnancy if the benefits to the mother outweigh the possible risks to the fetus. Magnefar should not be used in combination with vitamin-mineral complex preparations for pregnant women. During lactation, taking Magnefar is possible only after the issue of possible interruption of breastfeeding has been resolved.
Interaction with other drugs: There is a mutual decrease in intestinal absorption with the combined use of the drug Magnefar with theophylline, tetracyclines, fluoroquinolone antibiotics, anticoagulant agents warfarin derivatives, iron preparations, phosphates, as well as calcium salts (if it is necessary to use these drugs in combination, the interval between their receptions for at least 3 hours). There is an increased need for pyridoxine hydrochloride in patients receiving therapy with hydralazine, cycloserine, isoniazid, oral contraceptives and penicillamine. Pyridoxine hydrochloride, when used in combination, can induce the metabolism of levodopa and reduce the severity of its therapeutic effect (the maximum recommended daily dose of Magnefar for patients receiving levodopa is 1 tablet).
Diuretics may decrease the half-life of magnesium by increasing its excretion by the kidneys. However, with prolonged use of potassium-sparing diuretics simultaneously with the drug Magnefar, patients may develop hypermagnesemia due to increased resorption of magnesium in the renal tubules. Caution should be exercised when using Magnefar simultaneously with other magnesium-containing drugs (including laxatives and antacids). Caution should be exercised when prescribing Magnefar to patients receiving digitalis preparations.
Overdose: The use of high doses of Magnefar, as a rule, does not cause the development of toxic effects. Mainly when using excessive doses of magnesium in patients with impaired renal function or when using the drug Magnefar in doses that are tens of times higher than recommended, the development of vomiting, diarrhea, arterial hypotension, arrhythmia, myasthenia gravis, respiratory depression, and pain in the extremities is possible. In addition, with magnesium intoxication, it is possible to develop disturbances in temperature sensitivity and decreased tendon reflexes.
Calcium salts are a specific antidote for magnesium. In case of an overdose of Magnefar, gastric lavage is performed and enterosorbents are prescribed. In case of severe intoxication, intravenous administration of calcium salts (for example, calcium gluconate) at a dose of 2.5-5 mmol per 1 kg of body weight (in terms of pure calcium) is indicated.
Release form: Magnefar tablets in blister packs of 10 pieces, 6 blister packs are included in a cardboard pack.
Storage conditions: The drug Magnefar should be stored for no more than 3 years after release in rooms with a temperature that does not exceed 25 degrees Celsius.
Synonyms: Magvit, Magnicum, Magne-B6.
Composition: 1 tablet of Magnefar contains: Magnesium hydroaspartate tetrohydrate – 500 mg (in terms of magnesium – 34 mg); Pyridoxine hydrochloride – 5 mg; Additional ingredients.
Attention! The description of the drug " Magnefar " on this page is a simplified and expanded version of the official instructions for use. Before purchasing or using the drug, you should consult your doctor and read the instructions approved by the manufacturer. Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.
